Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Stellar Announces New Board Members

Published: Wednesday, August 22, 2012
Last Updated: Wednesday, August 22, 2012
Bookmark and Share
Appointment of Gregory T. Baxter and Mike Sampat to Board.

Stellar Biotechnologies, Inc. has announced that Gregory T. Baxter, Ph.D. and Mike Sampat have been appointed to the Board of Directors.

Stellar’s President & CEO, Frank Oakes said, “These two key appointments are important to the Company as they strengthen our independent corporate governance while adding a director who is a financial and deal-savvy CPA in Mike Sampat to fill the vacancy left by the passing of our board member Harvey Wright, and Greg Baxter, a scientist with experience as an executive and director in a number of biotech companies and institutions, including the National Science Foundation (NSF), where he had the opportunity to work closely with the Stellar team during the past three years. The independent perspective that Mike and Greg will bring, and the combination of experience in financial management, fund raising, and strong ties to the biotechnology industry bring strength to the board in key areas and should provide great support and guidance to the Company’s executive team.”

New director, Mike Sampat said, “I’m excited to join the Stellar board as the Company continues to grow to be a prime supplier of high-quality KLH to the pharmaceutical industry and look forward to expanding the capital base to fund the future growth.”

New board member, Greg Baxter said, “Stellar Biotechnologies is an exciting and innovative company and a leader in the sustainable manufacture of an important immune stimulating protein critical for the production of therapeutic vaccines and immunodiagnostics products. I am excited to be a part of the Stellar team and to have the opportunity to participate in the growth of the Company.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Stellar Announces Issuance of Patents for C. diff Immunotherapy Technology
Issuance of two additional patents in U.S. and China.
Tuesday, December 10, 2013
Stellar Presents Preclinical Poster on C. diff Active Immunotherapy
Poster presented at 7th Vaccine and ISV Congress being held in Spain.
Tuesday, October 29, 2013
Stellar’s Immunotherapy Technology Demonstrates Protection Against C. diff Infection
Study results presented this week at ClostPath 8 in Australia, October 22-26, 2013.
Tuesday, October 22, 2013
Stellar Acquires Exclusive, Worldwide License to C. diff Immunotherapy Technology
Stellar expands with proprietary KLH-based vaccine program.
Wednesday, July 31, 2013
Stellar Announces Chow and Brisson to New C-Level Posts
Herbert S. Chow and Catherine Brisson appointed to the position of CTO and CPO respectively.
Tuesday, August 14, 2012
Stellar Announces Exclusive Option to License Clostridium Difficile Technology
Stellar executes agreement with University of Guelph for vaccine research.
Wednesday, April 11, 2012
Stellar Biotechnologies Announces Investor Relations Agreement
Stellar Biotechnologies, Inc. is pleased to announce that it has retained TheBiotechPanel, Inc. to provide the Company with investor relations services, for an initial period of six months.
Wednesday, January 18, 2012
Stellar Biotechnologies Announces a Strategic Agreement for Marketing and Sales with SAFC®
Stellar will produce KLH commercial intermediate and SAFC will sell, distribute and market cGMP-grade HMW KLH.
Friday, August 05, 2011
Stellar Biotechnologies Announces Appointment of New Director, David L. Hill, Ph. D.
Dr. Hill, is a Board Certified High Complexity Laboratory Director, Board Certified Embryology Laboratory Director and member of the American Association of Bioanalysts.
Friday, May 27, 2011
Stellar Biotechnologies Appoints Vice President, Business Development & Marketing
Company Executive VP, Darrell Brookstein's title will be changed to Executive VP, Corporate Development & Finance.
Wednesday, March 09, 2011
Scientific News
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos